| Also known as |
Cangliflozin |
| Blood pressure |
Can lead to a reduction in blood pressure |
| Chemical name |
(2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Dosage (medical) |
Typically 100 mg once daily, may increase to 300 mg based on efficacy and tolerability |
| Dosage (sports) |
Not applicable as it is not indicated for performance enhancement |
| Effects |
Lowers blood sugar levels in type 2 diabetes patients |
| Formula |
C24H25ClO5 |
| Half-life |
Approximately 10.6 hours to 13.1 hours |
| Hepatotoxicity |
Low risk of hepatotoxicity |
| Lab Test |
May interfere with 1,5-anhydroglucitol (1,5-AG) assay, leading to underestimation of serum 1,5-AG levels and false reports of glycemic control |
| Main action |
Reduces blood glucose by inhibiting sodium-glucose transport protein 2 in the kidneys, leading to glucose excretion through urine |
| Side effects |
Urinary tract infections, yeast infections, increased urination, risk of lower limb amputation, ketoacidosis, severe dehydration, hypotension |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
100 mg |
| Substance class |
SGLT2 inhibitor |
| Trade name |
Invokana |
| Use in sports |
None, not used for performance enhancement |
| Water Retention |
Does not cause significant water retention, may actually promote fluid loss due to glycosuria |
| Manufacturer |
Pharmaceutical |
